An individual participant data meta-analysis clarifies which elements of collaborative care most effectively reduce depressive symptoms in primary care, informing implementation strategies for clinicians...
A randomized clinical trial evaluated whether a 6-month habit-focused lifestyle program could improve sustained remission of metabolic syndrome at 24 months compared with standard education and activity...
The FDA has approved a supplemental indication for lumateperone to reduce relapse risk in adults with schizophrenia based on phase 3 randomized withdrawal data.
A systematic review and meta-analysis evaluated whether pharmacist-led deprescribing interventions reduce polypharmacy and potentially inappropriate medications among older adults across care settings.
...
A stepped-wedge cluster randomized trial evaluated whether pairing electronic decision support with routine medication reviews increases deprescribing of potentially inappropriate medications among older...
New reports detail the spread of SARS-CoV-2 variant BA.3.2, Long COVID disability burden, sarbecovirus cross-immunity, and how stacked outpatient risk factors shape severe COVID-19 outcomes.
March 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
The FDA has granted full approval for the use of brexucabtagene autoleucel in adults with relapsed or refractory mantle cell lymphoma, based on confirmatory ZUMA-2 data.
In a phase 3 randomized trial, investigators evaluated whether finerenone added to the background renin–angiotensin system blockade, thereby reducing albuminuria in adults with type 1 diabetes and chronic...
